Prazitone
Clinical data | |
---|---|
Other names | AGN-511; 5-Phenyl-5-(2-piperidylmethyl)barbituric acid |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H19N3O3 |
Molar mass | 301.346 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Prazitone (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name; developmental code name AGN-511) is a barbiturate derivative described as an antidepressant which was developed in the 1960s.[1][2] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[3][1] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.
References
- ^ a b Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1011. ISBN 978-1-4757-2085-3. Retrieved 20 October 2024.
- ^ DE 1645911, Wiggins LF, Gittos MW, James JW, "Process for the preparation of derivatives of barbituric acid", issued 30 May 1973, assigned to Aspro Nicholas Ltd.
- ^ US 3806596, Langlands R, "Method for imparting anti-depressant and/or anxiolytic effects to animals.", issued 23 March 1974, assigned to Aspro Nicholas Ltd.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.